A total of 3703 patients experienced a myocardial infarction (3341 patients in GLP1-RA trials and 362 patients in finerenone trials), 2042 experienced a stroke (1646 patients in GLP1-RA trials and 396 patients in finerenone trials), and 3395 experienced a cardiovascular death (2709 in GLP1-RA trials and 686 patients in finerenone trials). Here, GLP1R is linked to myocardial infarction.